Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

iShares Core MSCI Emerging Markets ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares Core MSCI Emerging Markets ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $80.87, while Regeneron Pharmaceuticals Inc trades at $796.21 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares Core MSCI Emerging Markets ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.

IEMGREGN
Sector
Broad Market / FactorHealth
52-Week High
$86.00$812.27
52-Week Low
$61.76$555.51
Market Cap
$82.06B
Enterprise Value
$76.77B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI Emerging Markets ETF

IEMG trades at $81.10, up 1.93% with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% trailing returns but faces elevated volatility. Recent news highlights IEMG's 40% technology weighting and AI exposure in emerging markets, though some analysts caution about concentration risks after significant gains.

The outlook remains positive given attractive emerging market valuations and AI-driven growth potential, but investors should monitor volatility and geopolitical risks. The ETF's low 0.09% expense ratio and diversification across 2,700 stocks provide cost-effective exposure to developing economies with superior dividend growth prospects.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.

Returns comparison

Trailing returns across standard periods

About iShares Core MSCI Emerging Markets ETF

IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.

Read more on IEMG

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN